Oppenheimer analyst Michael Wiederhorn maintains $HCA Healthcare (HCA.US)$ with a buy rating, and adjusts the target price from $390 to $400.
According to TipRanks data, the analyst has a success rate of 66.1% and a total average return of 16.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $HCA Healthcare (HCA.US)$'s main analysts recently are as follows:
The forecast for HCA Healthcare was adjusted with expectations of financial figures falling short of the market consensus, reversing a trend of surpassing projections. This adjustment comes in the wake of disturbances attributed to hurricanes. Despite the recent decline in stock value, there is an anticipation of a potential phase of stabilization.
Despite the challenges posed by the recent hurricanes, HCA Healthcare's Q3 results managed to surpass these adversities. It is anticipated that these effects will persist into Q4, influencing FY2024 guidance towards the lower spectrum. Nevertheless, the company's management forecasts that earnings growth for 2025 will meet or exceed their long-term objectives, supported by an admissions growth trajectory that is projected to exceed the norm by 3%-4%.
After the release of 3Q24 results, expectations from investors were high, yet HCA Healthcare's underlying performance remained strong with same-store revenues increasing by 7.1%, compared to the 7.9% comparative period in the previous year.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奥本海默控股分析师Michael Wiederhorn维持$HCA医疗 (HCA.US)$买入评级，并将目标价从390美元上调至400美元。
根据TipRanks数据显示，该分析师近一年总胜率为66.1%，总平均回报率为16.2%。
此外，综合报道，$HCA医疗 (HCA.US)$近期主要分析师观点如下：
对HCA Healthcare的预测进行了调整，预计财务数据将低于市场共识，扭转了超出预期的趋势。这种调整是在飓风引起的干扰之后进行的。尽管最近股票价值下跌，但预计可能进入稳定阶段。
尽管最近的飓风带来了挑战，但HCA Healthcare的第三季度业绩还是成功克服了这些逆境。预计这些影响将持续到第四季度，从而影响 FY2024 对较低频谱的指导。尽管如此，该公司的管理层预测，2025年的收益增长将达到或超过其长期目标，这得益于招生增长轨迹，预计将超过正常水平3％-4％。
在公布24年第三季度业绩后，投资者的期望很高，但HCA Healthcare的基本表现仍然强劲，同店收入增长了7.1％，而去年同期为7.9％。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
